Phase I Study of Bortezomib (Velcade) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma.

Trial Profile

Phase I Study of Bortezomib (Velcade) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Mesna; Methotrexate; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
    • 10 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2019.
    • 14 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top